Salestools LogoSalestools
Salestools AI Agents
Solutions
Resources
Company
Pricing
Salestools Logo

Salestools

The #1 AI Agent for Sales teams and Go To Market teams. Sell more, faster, with less effort.

Product

  • AI Sales Agents
  • Intent Data
  • Technology Data
  • Visitor Tracking
  • Co-Pilot
  • Social Selling

Solutions

  • Customer Service
  • E-commerce
  • SaaS
  • Enterprise
  • Small Business

Resources

  • The Report
  • Documentation
  • API Reference
  • Help Center
  • Blog
  • Case Studies
  • Webinars

Company

  • About
  • Careers
  • Press
  • Contact
  • Partners

Our locations

  • New York, HQ
  • Bucharest, AI Research Lab
  • Zug, Switzerland

Β© 2026 Salestools. All rights reserved.

Data Terms & SecurityPrivacy PolicyTerms of Service
All systems operational
Salestools LogoSalestools
Salestools AI Agents
Solutions
Resources
Company
Pricing
Back to Reports
Biotech

Seattle Genetics

Seattle Genetics raises $35B Public at $38B valuation

21823 30th Drive SE, Bothell, WA 98021January 1, 20241 min read
Total Raised
$35B
Valuation
$38B
Latest Round
Public
Employees
2000+

Seattle Genetics: Public Funding Round

Seattle Genetics has successfully raised $35B in Public funding, reaching a valuation of $38B.

Company Overview

Biotechnology company

Funding Details

The Public round was led by Public.

Company Information

  • Headquarters: 21823 30th Drive SE, Bothell, WA 98021
  • Founded: 1998
  • Employees: 2000+
  • Category: Biotech

Investment

Seattle Genetics plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

  • Public: Verified investor in Public

Company Info

Headquarters
21823 30th Drive SE, Bothell, WA 98021
Founded
1998
Team Size
2000+
Last Round
$35B(Jan 2024)

Investors (1)

P
PublicLead
Lead Investor
Verified investor in Public

Topics

verified(3079)real-funding(3079)public(927)seattle-geneticsbiotech21823-30th-drive-se

Share

Related Reports

Biotech
AusperBio

AusperBio Raises $73M Series B

Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials

David Chen
David Chen
Dec 30, 2025
0 min readβ€’$73M Series B
Biotech
Orna Therapeutics

Orna Therapeutics Raises $251M Series B

Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases

Emma Rodriguez
Emma Rodriguez
Oct 23, 2025
0 min readβ€’$251M Series B
Biotech
Forge Biologics

Forge Biologics Raises $120M Series C

Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min readβ€’$120M Series C

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free